1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shandong Wohua Pharmaceutical Co., Ltd. Class A

Shandong Wohua Pharmaceutical Co., Ltd. Class A

SSZSE:002107
6.12
CNY
0.00
(0.00%)
0.20EPS
27.51P/E
3.28BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.41
0.76
0.82
1.01
1.27
1.38
1.53
1.74
1.62
1.8
1.55
1.26
1.45
1.35
Basic EPS, GAAP
0.02
0.08
0.12
0.09
0.1
0.08
0.17
0.31
0.28
0.19
0.1
0.06
0.17
0.21
Free Cash Flow per Basic Share
- -
0.05
0.22
0.08
0.19
0.08
- -
0.25
0.31
0.32
0.22
0.14
0.23
- -
Dividend per Share
- -
0.02
0.06
0.06
- -
- -
0.03
0.08
0.27
0.27
- -
0.24
0.12
0.14
Book Value per Share
1.05
1.28
0.83
0.85
0.95
1.03
1.16
1.4
1.42
1.29
1.4
1.21
1.25
1.23
Tangible Book Value per Share
0.95
1.09
0.64
0.68
0.82
0.91
1.03
1.22
1.27
1.17
1.27
1.09
1.14
1.11
Basic Weighted Avg Shares
623
578
571
558
570
562
564
577
584
565
588
607
563
586
Sales/Revenue/Turnover
256
438
469
563
727
774
860
1,006
943
1,015
910
764
817
793
Operating Margin (%)
2.52
9.72
17.32
12.87
16.76
7.09
13.16
21.53
21.95
11.08
5.77
5.62
11.84
17.06
Depreciation Expense
15
22
22
19
20
19
19
28
33
35
33
32
32
- -
Net Income, GAAP
11
43
71
49
57
46
96
179
163
107
59
36
96
121
Effective Tax Rate (%)
0.03
3.25
4.16
12.37
11.89
8.27
13.89
15.48
15.07
18.87
14.66
20.84
13.27
11.78
Profit Margin (%)
4.16
9.9
15.22
8.67
7.85
5.89
11.14
17.78
17.33
10.58
6.46
4.77
11.72
15.27
Working Capital
365
474
264
285
349
349
406
371
417
316
385
301
326
323
LT Debt
- -
- -
30
30
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
Total Equity
605
801
547
573
656
696
775
918
929
790
833
723
721
704
Return on Invested Capital (%)
1.5
5.86
10.75
9.81
12.42
5.81
12.95
19.79
15.84
10.35
5.81
4.48
12.27
16.38
Return on Capital (%)
1.33
5.03
8.82
6.13
6.45
7.74
12.83
18.63
16.64
14.52
8.73
5.01
14.19
16.9
Return on Common Equity (%)
1.77
6.44
11.73
10.11
11
7.99
15.13
24.18
20.07
13.7
7.57
4.85
13.47
16.97

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
577
577
577
Market Capitalization
3,602
3,729
3,284

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
567
539
560
Cash, Cash Equivalents & STI
394
373
386
Accounts Receivable, Net
67
54
52
Inventories
93
96
109
Total Current Liabilities
241
256
237
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.33%
-4.36%
-0.28%
Free Cash Flow
-2,501.04%
2.3%
45.59%
Net Income, GAAP
19.85%
7.33%
162.93%
Sales/Revenue/Turnover
6.57%
-3.62%
6.96%
Total Cash Common Dividend
- -
- -
-52%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
215
180
182
187
764
2025
218
208
- -
192
817
2026
219
174
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
0.02
0.02
0.06
2025
0.04
0.04
- -
0.05
0.17
2026
0.06
0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.24
2025
- -
- -
- -
- -
0.12
2026
0.14
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Shengting Li
Full Time Employees
1,018
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 3517 Liyuan Street Weifang SD China 261205
IPO Date
Jan 24, 2007
Website
wohua.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ) researches, develops, manufactures and markets proprietary Chinese medicines principally targeting cardiovascular, cerebrovascular, nervous system, orthopedic, respiratory and pediatric diseases; its core products include Xinkeshu tablets (Wohua Xinkeshu tablets) for cardiovascular conditions, Hedan tablets and capsules (Hodan) for cerebrovascular ailments, Gusu Kang capsules and granules (osteoporosis products), Naoxueshu oral solutions, Brain Hemorrhage oral solution (Nao Xueshu), Amber Stone Granules, Yuandu Hanbi Liquid, and Orange Red Pear Paste, offered in forms such as tablets, hard capsules, granules, pills, oral liquids, mixtures, powders and ointments. Founded in 2003 with roots tracing back over 200 years to Wanhetang Pharmaceutical in China's Qing Dynasty, the company is headquartered in Weifang, Shandong province, China, and operates production facilities including subsidiaries Jiangxi Wohua Jishun Pharmaceutical Co., Ltd. and Liaoning Wohua Kangchen Pharmaceutical Co., Ltd., acquired in 2015 to expand its resource-sharing network. Recent developments encompass the launch of Biliqi lysine calcium hydrogen phosphate granules at Wohua Kangchen leveraging surplus capacity, a strategic partnership with 1YaoWang (1drug network) to build a cardiovascular "medicine + service" ecosystem, publication of expert consensus on Xinkeshu tablets for coronary heart disease with anxiety/depression, award of Shandong Science and Technology Progress Second Prize for Xinkeshu research, and initiation of a registration study for Brain Hemorrhage oral solution.